Neutropenia - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Neutropenia - Pipeline Review, H1 2016', provides an overview of the Neutropenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Neutropenia - The report reviews pipeline therapeutics for Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Neutropenia therapeutics and enlists all their major and minor projects - The report assesses Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Neutropenia Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Neutropenia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Neutropenia Overview 9 Therapeutics Development 10 Pipeline Products for Neutropenia - Overview 10 Neutropenia - Therapeutics under Development by Companies 11 Neutropenia - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Neutropenia - Products under Development by Companies 17 Neutropenia - Companies Involved in Therapeutics Development 18 Apotex Inc. 18 Biogenomics Limited 19 Cellerant Therapeutics, Inc. 20 Coherus BioSciences, Inc. 21 Dr. Reddy's Laboratories Limited 22 Ligand Pharmaceuticals, Inc. 23 NAL Pharmaceuticals Ltd. 24 Prolong Pharmaceuticals, LLC 25 Richter Gedeon Nyrt. 26 Sandoz International GmbH 27 Therapeutic Proteins International, LLC 28 Toko Pharmaceutical Industries Co., Ltd. 29 USV Limited 30 Neutropenia - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 ACN-8337 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 EC-18 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 filgrastim - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 filgrastim - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 filgrastim - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 filgrastim - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 LG-7455 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 pegfilgrastim - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 pegfilgrastim - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 pegfilgrastim - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 pegfilgrastim - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 pegfilgrastim - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 pegfilgrastim - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 pegfilgrastim - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 pegfilgrastim - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 pegfilgrastim - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 pegfilgrastim - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 pegfilgrastim (recombinant) - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 romyelocel-L - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 ST-7 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 tamibarotene - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Neutropenia - Recent Pipeline Updates 63 Neutropenia - Dormant Projects 68 Neutropenia - Product Development Milestones 70 Featured News & Press Releases 70 Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim 70 Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study 70 Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701 71 Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program 71 Dec 08, 2015: EMA started the evaluation of Richter's marketing authorisation application for biosimilar pegfilgrastim 72 Dec 07, 2015: Phase III Data Shows Sandoz' Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product 72 Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA 73 Oct 01, 2015: Coherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study 74 Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study 75 Dec 17, 2014: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Pegfilgrastim 75 Appendix 76 Methodology 76 Coverage 76 Secondary Research 76 Primary Research 76 Expert Panel Validation 76 Contact Us 76 Disclaimer 77
List of Tables
Number of Products under Development for Neutropenia, H1 2016 10 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Comparative Analysis by Unknown Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Neutropenia - Pipeline by Apotex Inc., H1 2016 18 Neutropenia - Pipeline by Biogenomics Limited, H1 2016 19 Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H1 2016 20 Neutropenia - Pipeline by Coherus BioSciences, Inc., H1 2016 21 Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 22 Neutropenia - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 23 Neutropenia - Pipeline by NAL Pharmaceuticals Ltd., H1 2016 24 Neutropenia - Pipeline by Prolong Pharmaceuticals, LLC, H1 2016 25 Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2016 26 Neutropenia - Pipeline by Sandoz International GmbH, H1 2016 27 Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H1 2016 28 Neutropenia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2016 29 Neutropenia - Pipeline by USV Limited, H1 2016 30 Assessment by Monotherapy Products, H1 2016 31 Number of Products by Stage and Target, H1 2016 33 Number of Products by Stage and Mechanism of Action, H1 2016 35 Number of Products by Stage and Route of Administration, H1 2016 37 Number of Products by Stage and Molecule Type, H1 2016 39 Neutropenia Therapeutics - Recent Pipeline Updates, H1 2016 63 Neutropenia - Dormant Projects, H1 2016 68 Neutropenia - Dormant Projects (Contd..1), H1 2016 69
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.